RE: #invladwebelieve in science17 Apr 2021 01:20
Meh, screw it, I will make my prediction, please note, no inside information, just a guess:
1, I think its a given that the licencing agreement will include a clause that gives Eli Lilly first refusal at licencing CDX, I suspect they may even agree a maximum price now but not reveal it with right to licence after phase 1/2a.
2, I suspect it will include a loan facility the company can access if required, some sort of replacement to Mint.
3, I cannot see Vlad being able to offer any decent sort of cash amount for the IP so instead a % of hemogenyx, either something like a straight 10% allocation of shares or perhaps a 20% placing of shares with Eli investing cash.
4, A significant % of any royalties from the sale of CDX should they chose not to licence and Hemo licence to another Pharma, IMO a massive figure like 40-50% (just a guess but they are in a powerful position)
5, Eli Lilly continue to fund and progress CDX up to the point of IND application but from there it moves to Phase 1/2a trials.
I THINK Eli will want hemo to do the trials themselves, its hard to stay anonymous (lets face it they are still being referred to as Global Co, they dont want to be known). By having Hemo find someone else to run the clinical trials if something goes wrong Eli can walk away whistling and no bad PR (They have had alot of bad PR recently). If things go well? Well they have the rights to licence it on the cheap.
Anyway, thats my GUESS, its not a brilliant offer for Hemo but to me its fair, it gives Hemo the chance to prove it works and gives Eli a potentially valuable product if it works on the cheap. Maybe some of it is accurate, maybe not, be pleased to see what others sensible thoughts on it are. Read the RNS, there is going to be SOME relationship there, Eli are not a charity, and they need Hemo to succeed:
"exact terms of the licence and GlobalCo's continued involvement in the progression of CDX toward clinical trials."
Sign In
Follow the stocks
